Hot Pursuit     02-Nov-23
Dr Lal PathLabs spurts as Q2 PAT climbs 53% YoY To Rs 111 cr
Dr Lal PathLabs rallied 3.30% to Rs 2,455.55 after the company's consolidated net profit soared 52.9% to Rs 110.7 crore in Q2 FY24 as against Rs 72.4 crore recorded in Q2 FY23.

Revenue from operations grew by 12.6% year on year to Rs 601.3 crore in the quarter ended 30 September 2023.

The company’s revenue (excluding RTPCR) increased by 14.4% YoY in Q2 FY24.

Profit before tax in Q2 FY24 stood at Rs 152.2 crore, registering a growth of 48.05% from Rs 102.8 crore in Q2 FY23.

EBITDA jumped 23.6% to Rs 178 crore during the quarter as against Rs 144 crore reported in Q2 FY23. EBITDA margin improved to 29.6% in the September quarter as compared to 26.9% recorded in the corresponding quarter previous year.

Dr. Om Manchanda, managing director of Dr Lal PathLabs, said, “We are seeing healthy and steady rise in DLPL’s revenue growth trends both in value and volume terms. The quarter also saw some rationality returning, where brands have taken measured price increases in their test portfolios. DLPL continues to move levers in order sustain performance momentum. From focus on Tier 3 and 4 towns in strong markets of North and East to emphasizing upon specialty and super specialist portfolio; we have meticulously pursued growth drivers in this endeavor. We continue to build Suburban in key markets of West like Mumbai, Pune and Goa, there’s a clear focus on driving topline while optimizing laboratory infrastructure between our two brands.”

Bharath Uppiliappan, chief executive officer, of Dr Lal PathLabs, stated, “We reported robust quarter of revenue and profit growth while making good progress to our strategic growth agendas. Our patient growth is significantly higher than our Q1 FY24 numbers, we served 7.5 million patients in the second quarter of FY24 and 14.4 million patients in H1 of FY24.

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. The company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. As on 31 March 2023 the company has 277 clinical laboratories, 5,102 patient service centers (PSCs) and 10,938 pick-up points (PUPs).

Previous News
  Dr Lal Pathlabs
 ( Results - Analysis 13-May-24   10:51 )
  Dr Lal Pathlabs
 ( Results - Analysis 12-May-23   10:22 )
  Dr Lal Pathlabs
 ( Results - Analysis 28-Jul-23   11:08 )
  Dr Lal Pathlabs
 ( Results - Analysis 02-Feb-23   18:25 )
  Dr. Lal PathLabs to hold AGM
 ( Corporate News - 29-Jul-23   12:52 )
  Dr. Lal PathLabs to conduct board meeting
 ( Corporate News - 25-Jan-24   17:55 )
  Dr. Lal PathLabs to conduct board meeting
 ( Corporate News - 03-May-24   14:32 )
  Dr. Lal PathLabs to declare Quarterly Result
 ( Corporate News - 02-Nov-22   15:51 )
  Dr Lal Pathlabs consolidated net profit declines 39.37% in the December 2021 quarter
 ( Results - Announcements 10-Feb-22   15:46 )
  Dr. Lal PathLabs Q2 PAT slides 24% YoY to Rs 72 cr
 ( Hot Pursuit - 08-Nov-22   15:42 )
  Dr. Lal PathLabs to announce Quarterly Result
 ( Corporate News - 06-May-22   16:46 )
Other Stories
  Tata Motors total sales drop 11% YoY in Sept’24
  01-Oct-24   15:33
  Vipul Organics hits all-time high after board OKs Rs 25 cr right issue
  01-Oct-24   15:06
  Magellanic Cloud Ltd leads losers in 'A' group
  01-Oct-24   15:00
  Kamdhenu Ventures Ltd leads losers in 'B' group
  01-Oct-24   14:45
  GE Power India rises on bagging order worth Rs 240-cr
  01-Oct-24   14:41
  Volumes jump at Caplin Point Laboratories Ltd counter
  01-Oct-24   14:30
  TVS Motor registers 20% growth in September 2024 sales; Q2 total sales at 12.28 lakh units
  01-Oct-24   14:07
  Oil and Gas shares slide
  01-Oct-24   14:00
  Telecom shares fall
  01-Oct-24   14:00
  Real Estate stocks slide
  01-Oct-24   14:00
Back Top